While the Overweight rating suggests that Morgan Stanley continues to see Cabaletta Bio as a good investment, the reduction in the price target may reflect a more cautious view of the company's near-term price potential. This could lead to mixed reactions in the market, with some investors seeing the lowered target as a sign to adjust expectations, while others may focus on the continued positive rating.